Accéder au contenu
Merck

The ferroportin Q248H mutation protects from anemia, but not malaria or bacteremia.

Science advances (2019-09-14)
John Muthii Muriuki, Alexander J Mentzer, Gavin Band, James J Gilchrist, Tommy Carstensen, Swaib A Lule, Morgan M Goheen, Fatou Joof, Wandia Kimita, Reagan Mogire, Clare L Cutland, Amidou Diarra, Anna Rautanen, Cristina Pomilla, Deepti Gurdasani, Kirk Rockett, Neema Mturi, Francis M Ndungu, J Anthony G Scott, Sodiomon B Sirima, Alireza Morovat, Andrew M Prentice, Shabir A Madhi, Emily L Webb, Alison M Elliott, Philip Bejon, Manjinder S Sandhu, Adrian V S Hill, Dominic P Kwiatkowski, Thomas N Williams, Carla Cerami, Sarah H Atkinson
RÉSUMÉ

Iron acquisition is critical for life. Ferroportin (FPN) exports iron from mature erythrocytes, and deletion of the Fpn gene results in hemolytic anemia and increased fatality in malaria-infected mice. The FPN Q248H mutation (glutamine to histidine at position 248) renders FPN partially resistant to hepcidin-induced degradation and was associated with protection from malaria in human studies of limited size. Using data from cohorts including over 18,000 African children, we show that the Q248H mutation is associated with modest protection against anemia, hemolysis, and iron deficiency, but we found little evidence of protection against severe malaria or bacteremia. We additionally observed no excess Plasmodium growth in Q248H erythrocytes ex vivo, nor evidence of selection driven by malaria exposure, suggesting that the Q248H mutation does not protect from malaria and is unlikely to deprive malaria parasites of iron essential for their growth.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Human TF / Serotransferrin ELISA Kit